Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioLTS:0HX7 +1.94%23 Debt-to-EBITDA is -0.16 as of Jun. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 23/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 303 Biotechnology companies, Adicet Bio ranks worse than 330032.67% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Adicet Bio's Debt-to-EBITDA or its related term are showing as below:
LTS:0HX7'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.57 Med: -0.23 Max: -0.13
Current: -0.14
During the past 8 years, the highest Debt-to-EBITDA Ratio of Adicet Bio was -0.13. The lowest was -0.57. And the median was -0.23.
LTS:0HX7's Debt-to-EBITDA is ranked worse than 100% of 303
companies
in the Biotechnology industry
Industry Median: 1.27
vs LTS:0HX7: -0.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Adicet Bio Debt-to-EBITDA Related Terms
Adicet Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Adicet Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HX7 vs OKYO, GOSS, ACRV: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Adicet Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Adicet Bio (LTS:0HX7) has a Debt-to-EBITDA of -0.16 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adicet Bio. According to the industry distribution chart, Adicet Bio ranks #999999 out of 303 companies in the Biotechnology industry.
Is Adicet Bio's Debt-to-EBITDA too high?
Adicet Bio's current Debt-to-EBITDA is -0.16. Based on the distribution chart, Adicet Bio ranks #999999 out of 303 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Debt-to-EBITDA compare to OKYO and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 303 companies for Debt-to-EBITDA. This places Adicet Bio in the lower half of its industry. The industry median Debt-to-EBITDA is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.27, based on 303 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Adicet Bio. For the Biotechnology industry, the median Debt-to-EBITDA is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current Debt-to-EBITDA is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $9.56 — trading 2024.4% above its estimated fair value. The current Debt-to-EBITDA is -0.16. Adicet Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current Debt-to-EBITDA is -0.16 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicet Bio (LTS:0HX7) Overvalued in 2026?
Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued.
The current stock price of $9.56 is trading 2024.4% above its estimated GF Value™ of $0.45.
GuruFocus considers Adicet Bio to be Significantly Overvalued.
Key valuation signals for LTS:0HX7:
Debt-to-EBITDA: -0.16
GF Value™: $0.45 vs. price of $9.56 (2024.4% above fair value)
No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
23GF Score
Get the complete analysis for LTS:0HX7
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HX7 has been successfully added to your 
